Context Therapeutics Highlights CT-95 and CT-202 Programs at SITC Annual Meeting
ByAinvest
Friday, Nov 7, 2025 7:31 am ET1min read
CNTX--
Context Therapeutics presented two posters at the 2025 SITC Annual Meeting, highlighting its CT-95 and CT-202 programs. CT-95, a mesothelin x CD3 bispecific TCE, is in an ongoing Phase 1 trial with no cytokine release syndrome greater than Grade 2 and no dose-limiting toxicity observed. CT-202, a Nectin-4 x CD3 bispecific TCE, demonstrates potent preclinical activity with a favorable pharmacokinetic and safety profile, supporting its transition into clinical studies. Context anticipates providing initial Phase 1a data for CT-95 in mid-2026 and initiating a first-in-human trial for CT-202 in Q2 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet